Full Press Release Details
Announces the Withdrawal of a Class Action Lawsuit against it
YORK, TORONTO, and HERZLIYA, Israel - December 5, 2022 - InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR)
(dba Canndoc)("InterCure" or the "Company") is pleased to announce the withdrawal of a class action
lawsuit against it (the "Regenera Lawsuit"). The Regenera Lawsuit was described in the Company's press release
dated May 26, 2020 and in the Company's most recent Annual Report and Annual Information Form and it was primarily concerning a
motion to certify, as a class action, a claim filed against the Company, its directors and its executive officers, alleging that the
Company violated its obligation to publicly disclose certain events and developments which impacted the valuation of Regenera Pharma
Ltd. (in which the Company held a 11.76% position during the time relevant to the claim). On December 2, 2022, the Tel Aviv District
Court approved a consent motion to withdraw the Regenra Lawsuit, without any payment to the plaintiff from the Company.
InterCure (dba Canndoc)
(dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North
America. Canndoc, a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer and one of the first to
offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market
leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale"
model to lead the fastest growing cannabis global market outside of North America.
more information, visit: http://www.intercure.co.
Cohen, Chief Financial Officer